Heidelberg Pharma AG: US patent rights granted for diagnosis and treatment of patients with TP53/RNA polymerase II deletion
- Heidelberg Pharma’s partner MD Anderson Cancer Center receives patent rights from the US patent office for diagnosis and treatment of select patient groups with RNA polymerase II deletion
- Heidelberg Pharma holds an exclusive license to these patent rights
- Applicable as a biomarker to select particularly relevant patient groups for the entire ATAC platform
Heidelberg Pharma AG today announced that the partner University of Texas, MD Anderson Cancer Center, Houston, TX, USA, (MD Anderson), was granted patent rights related to the diagnosis and treatment of patients with RNA polymerase II deletion. The patent application is named “Methods Of Treating Cancer Harbouring Hemizygous Loss Of TP53” and was submitted at the US patent office by MD Anderson. Heidelberg Pharma holds an exclusive license to these patent rights.